A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C - Full Text View

Sponsored by:	University of Chicago
Information provided by:	University of Chicago
ClinicalTrials.gov Identifier:	NCT00814606

Purpose

This study seeks to evaluate the safety and efficacy of taking fluvastatin along with peginterferon alfa in previous partial responders with genotype 1 HCV.

Condition	Intervention	Phase
Hepatitis C Hepatitis C Virus	Drug: Fluvastatin Drug: Peginterferon alfa2a Drug: ribavirin	Phase II

MedlinePlus related topics: Hepatitis Hepatitis C

Drug Information available for: Ribavirin Peginterferon Alfa-2a Interferons Fluvastatin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Single Group Assignment
Official Title:	A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C

Further study details as provided by University of Chicago:

Primary Outcome Measures:

Efficacy of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment. [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Safety of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment. [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	5
Study Start Date:	December 2008
Estimated Study Completion Date:	October 2013
Estimated Primary Completion Date:	October 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Single Group: Experimental 8 weeks period of escalating doses of fluvastatin to a goal dose of 80mg daily, then patients will start treatment of HCV at week 9 with the usual standard of care protocol for medication dose, office visits and laboratories. Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks and ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks. Patients weighing < 75 kg will receive 1000mg per day (400mg in the morning and 600mg in the evening). Patients weighing ≥ 75 kg will receive 1200 mg per day (600mg in the morning and 600 mg in the evening).	Drug: Fluvastatin Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily Drug: Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9) Drug: ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)

Arms

Assigned Interventions

Single Group: Experimental

8 weeks period of escalating doses of fluvastatin to a goal dose of 80mg daily, then patients will start treatment of HCV at week 9 with the usual standard of care protocol for medication dose, office visits and laboratories. Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks and ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks. Patients weighing < 75 kg will receive 1000mg per day (400mg in the morning and 600mg in the evening). Patients weighing ≥ 75 kg will receive 1200 mg per day (600mg in the morning and 600 mg in the evening).

Drug: Fluvastatin

Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily

Drug: Peginterferon alfa2a

180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)

Drug: ribavirin

1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female of any ethnicity age 18 - 65 years with genotype 1 HCV
Previous partial responder to attempts at HCV therapy with PEG/RBV (at least 1 log drop but less than 2 log drop in HCV RNA at 12 weeks)
Previous history or serum HCV-RNA PCR quantifiable by Roche Amplicore HCV Test
A liver biopsy within 3 years of study enrollment consistent with HCV disease.
Compensated liver disease, Child-Pugh Class ≤ 6
Negative urine pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of the study drug
All patients enrolling in the study and all partners of study participants of childbearing potential must be using two reliable forms of effective contraception during the study. Exceptions may include partner/participant is surgically sterile.
Willingness to comply with study procedures and provide written informed consent

Exclusion Criteria:

AST or ALT > 10 ULN
Any investigational drug ≤ 12 weeks prior to the first of study drug
Prior intolerance to statin medications
Previous serious side effects to IFN or RBV (e.g. psychiatric side effect necessitating treatment discontinuation, severe cytopenia refractory to growth factors, intolerance to IFN/RBV requiring treatment discontinuation)
Any systemic antiviral therapy ≤ 24 weeks prior to the first dose of study drug or expectation that such treatment will be needed at any time during the study. Exception: Patients who have taken or are expected to require such treatment for herpetic lesions
Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc-IgM Ab ,or anti-HIV Ab
Serum concentrations of cerulplamin or alph-1-antitrypsin consistent with an increased risk of metabolic liver disease
History or other evidence of a medical condition associated with chronic liver disease (e.g. hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposure, nonalcoholic steatohepatitis)
Women who are pregnant or breastfeeding and male partners of woman who are pregnant or breastfeeding

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00814606

Contacts

Contact: Katie Wherity, RN

773-702-4477

kwherity@medicine.bsd.uchicago.edu

Locations

United States, Illinois
The University of Chicago	Recruiting
Chicago, Illinois, United States, 60637
Principal Investigator: K Gautham Reddy, MD

Sponsors and Collaborators

University of Chicago

Investigators

Principal Investigator:

K Gautham Reddy, MD

University of Chicago

More Information

Responsible Party:	The University of Chicago ( K Gautham Reddy, MD )
Study ID Numbers:	16336A
Study First Received:	December 23, 2008
Last Updated:	December 24, 2008
ClinicalTrials.gov Identifier:	NCT00814606
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Chicago:

genotype 1 hepatitis C
hepatitis C
HCV
liver

Study placed in the following topic categories:

Virus Diseases
Hepatitis
Liver Diseases
Digestive System Diseases
Interferons

Ribavirin
Peginterferon alfa-2a
Hepatitis, Viral, Human
Hepatitis C
Fluvastatin

Additional relevant MeSH terms:

Antimetabolites
Anti-Infective Agents
RNA Virus Infections
Molecular Mechanisms of Pharmacological Action
Flaviviridae Infections
Therapeutic Uses

Antilipemic Agents
Enzyme Inhibitors
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Antiviral Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009